Radiolabeled Monoclonal Antibody Therapy in Treating Adult Patients Who Have Recurrent Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma

OBJECTIVES:

- Assess the toxicity and therapeutic efficacy of yttrium Y 90 radiolabeled humanized
anti-Tac (HAT) monoclonal antibody in patients with Tac expressing hematologic
malignancies.

- Define the pharmacokinetics of indium In 111 and yttrium Y 90 HAT monoclonal
antibodies.

OUTLINE: This is a dose-escalation study.

Patients are given yttrium Y 90 labeled humanized anti-Tac monoclonal antibody (Y-HAT)
according to an escalating dose schedule along with a fixed dose of pentetic acid calcium
(Ca-DTPA) and indium In 111 labeled humanized anti-Tac monoclonal antibody (In-HAT). On day
1, Y-HAT and In-HAT are administered IV over 2 hours followed by a 5-hour infusion of
Ca-DTPA. Additional 5-hour infusions of Ca-DTPA are given on days 2 and 3. Treatment may
repeat every 6 weeks for up to 7 courses.

Cohorts of 3 to 6 patients are enrolled at each dose level. Dose escalation continues until
the maximum-tolerated dose (MTD) is determined. The MTD is defined as the dose preceding
that at which 2 or more patients experience dose-limiting toxicity. After the MTD is defined
the phase II portion of the study begins.

PROJECTED ACCRUAL: Approximately 65 patients will be accrued in phase I and an additional 30
patients in phase II.